IL-23
11 drugs Immunology
4
approved indications
11
Approved Drugs
10
Companies
10
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (10 companies)
✓ All 11 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (10 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
Johnson & Johnson 2 drugs
ALVOTECH USA INC 1 drug
Amgen 1 drug
By Therapeutic Area
Immunology 9 drugs
Other 2 drugs
Drugs by Company PRO
ALVOTECH USA INC 1 drug
Amgen 1 drug
AbbVie 1 drug
Fresenius Kabi 1 drug
BIO-THERA SOLUTIONS LTD 1 drug
ACCORD BIOPHARMA INC. 1 drug
BIOCON BIOLOGICS INC 1 drug
Eli Lilly 1 drug
SUN PHARMA GLOBAL 1 drug
By Therapeutic Area
Immunology 9 drugs
SELARSDI, WEZLANA, STELARA, OTULFI +5 more
Other 2 drugs
TREMFYA, SKYRIZI
Indications Treated
Plaque PsoriasisPsoriatic ArthritisCrohn’s DiseaseUlcerative ColitisModerate-to-severe plaque psoriasisActive psoriatic arthritisModerately to severely active ulcerative colitisModerately to severely active Crohn's diseaseCrohn's DiseaseCrohn Disease
All Drugs Targeting IL-23
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| SELARSDI | ALVOTECH USA INC | 2024 | 4 | Immunology |
| TREMFYA | Johnson & Johnson | 2017 | 4 | |
| WEZLANA | Amgen | 2023 | 4 | Immunology |
| STELARA | Johnson & Johnson | 2009 | 4 | Immunology |
| SKYRIZI | AbbVie | 2019 | 4 | |
| OTULFI | Fresenius Kabi | 2024 | 4 | Immunology |
| STARJEMZA | BIO-THERA SOLUTIONS LTD | 2025 | 4 | Immunology |
| IMULDOSA | ACCORD BIOPHARMA INC. | 2024 | 4 | Immunology |
| YESINTEK | BIOCON BIOLOGICS INC | 2024 | 4 | Immunology |
| OMVOH | Eli Lilly | 2023 | 2 | Immunology |
| ILUMYA | SUN PHARMA GLOBAL | 2018 | 1 | Immunology |